1,244 reports of this reaction
1.6% of all ARIPIPRAZOLE ORALLY DISINTEGRATING reports
#14 most reported adverse reaction
SCHIZOPHRENIA is the #14 most commonly reported adverse reaction for ARIPIPRAZOLE ORALLY DISINTEGRATING, manufactured by Accord Healthcare, Inc.. There are 1,244 FDA adverse event reports linking ARIPIPRAZOLE ORALLY DISINTEGRATING to SCHIZOPHRENIA. This represents approximately 1.6% of all 79,930 adverse event reports for this drug.
Patients taking ARIPIPRAZOLE ORALLY DISINTEGRATING who experience schizophrenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SCHIZOPHRENIA is a less commonly reported adverse event for ARIPIPRAZOLE ORALLY DISINTEGRATING, but still significant enough to appear in the safety profile.
In addition to schizophrenia, the following adverse reactions have been reported for ARIPIPRAZOLE ORALLY DISINTEGRATING:
The following drugs have also been linked to schizophrenia in FDA adverse event reports:
SCHIZOPHRENIA has been reported as an adverse event in 1,244 FDA reports for ARIPIPRAZOLE ORALLY DISINTEGRATING. This does not prove causation, but indicates an association observed in post-market surveillance data.
SCHIZOPHRENIA accounts for approximately 1.6% of all adverse event reports for ARIPIPRAZOLE ORALLY DISINTEGRATING, making it a notable side effect.
If you experience schizophrenia while taking ARIPIPRAZOLE ORALLY DISINTEGRATING, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.